Acrotech Biopharma Inc.
Clinical trials sponsored by Acrotech Biopharma Inc., explained in plain language.
Commercial-stage biopharma focused on oncology drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New study seeks safer dosing of cancer drug for patients with liver issues Results expected Feb 2027 (estimated)
-
New hope for rare blood cancer: Two-Drug combo trial launches
Disease control Recruiting nowThis phase 3 trial tests whether adding either belinostat or pralatrexate to standard chemotherapy helps people with newly diagnosed peripheral T-cell lymphoma live longer without their cancer getting worse. About 504 participants will be randomly assigned to one of three treatme…
Phase 3 • Sponsor: Acrotech Biopharma Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New study seeks safer dosing of cancer drug for patients with liver issues
Disease control Recruiting nowThis early-stage study tests the drug pralatrexate in 24 adults with advanced cancer and varying levels of liver function. The goal is to see how the body processes the drug and to find the right dose for people with mild, moderate, or severe liver impairment. Participants receiv…
Phase 1 • Sponsor: Acrotech Biopharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC